Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year



Grant | Alive

Total Raised


Last Raised

$150K | 12 yrs ago

About Zeomedix

Zeomedix is a pre-clinical stage company devoted to creating new therapies for infected and/or difficult to heal wounds utilizing the Company’s nitric oxide (NO) based platform technology. It is well known in the scientific literature that nitric oxide acts as a broad spectrum antimicrobial agent and enhances the wound healing process through changes in blood vessels. However, delivering nitric oxide to a wound site in a patient friendly manner has proven challenging because the molecule is gas. Zeomedix technology achieved controlled delivery of nitric oxide for treatment of skin and wound infections. Its initial product is a topical wound ointment that offers control of mild diabetic foot infections, a widespread and growing problem that leads to amputation and morbidity when left uncontrolled.

Zeomedix Headquarter Location

26 Ashlawn Circle

Malvern, Pennsylvania, 19355,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Zeomedix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zeomedix is included in 1 Expert Collection, including Diabetes.



1,750 items

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.